Compare · AZN vs NTHI
AZN vs NTHI
Side-by-side comparison of AstraZeneca PLC (AZN) and NeOnc Technologies Holdings Inc. (NTHI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and NTHI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 2153.7x NTHI ($122.2M).
- Over the past year, AZN is down 9.9% and NTHI is down 26.4% - AZN leads by 16.5 points.
- NTHI has been more active in the news (26 items in the past 4 weeks vs 14 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 3 for NTHI).
- Company
- AstraZeneca PLC
- NeOnc Technologies Holdings Inc.
- Price
- $169.66+1.75%
- $4.65-0.53%
- Market cap
- $263.10B
- $122.2M
- 1M return
- -0.09%
- +34.78%
- 1Y return
- -9.89%
- -26.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 14
- 26
- Recent ratings
- 25
- 3
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Latest NTHI
- Amendment: NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Leadership Update
- CEO Chen Thomas C bought $69,998 worth of shares (12,757 units at $5.49) (SEC Form 4)
- Amendment: Chief Scientific Officer Chen Thomas C bought $192,899 worth of shares (47,207 units at $4.09), increasing direct ownership by 7% to 583,531 units (SEC Form 4)
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEO Chen Thomas C bought $140,000 worth of shares (36,259 units at $3.86), increasing direct ownership by 7% to 583,531 units (SEC Form 4)
- CEO, President Heshmatpour Amir F bought $49,860 worth of shares (9,000 units at $5.54), increasing direct ownership by 0.29% to 3,096,000 units (SEC Form 4)
- NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
- CEO, President Heshmatpour Amir F bought $58,580 worth of shares (15,000 units at $3.91), increasing direct ownership by 0.49% to 3,087,000 units (SEC Form 4)
- These Nasdaq Stories Are Heating Up
- NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results